FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1887776136> ?p ?o ?g. }

• W1887776136 endingPage "1408" @default.
• W1887776136 startingPage "1402" @default.
• W1887776136 abstract "Study Type – Practice patterns (retrospective cohort) Level of Evidence 2b What is known on the subject? and what does the study add? There is no organized screening programme for prostate cancer in the UK, although men can request a PSA test at their general practice. The testing rate had been estimated at 6% per year among 45–84 year old men during 2001 to 2007. Our study estimated the annual practice-based PSA testing rate for men aged 45–89 years with no previous diagnosis of prostate cancer at 6.2% during 2007. This is very similar to the rate found in the earlier study. Older men and men at general practices situated in more affluent areas were found to be most likely to undergo a PSA test, suggesting that uptake of the test is not reflecting clinical need. OBJECTIVE • To estimate rates of prostate-specific antigen (PSA) testing in UK general practices by age, deprivation index and geographical location. SUBJECTS AND METHODS • Practice-based, retrospective data on PSA testing patterns in 2007 were collected from a random sample of 87 general practices using EMIS LV computer systems within the passively observed non-intervention arm of a cluster-randomized controlled trial. • Information for a total of 126 716 men aged 45–89 years with no recorded diagnosis of prostate cancer prior to 1 January 2007 was collected. RESULTS • In all, 7902 (6.2%) of 126 716 men aged 45–89 without a prior diagnosis of prostate cancer underwent at least one PSA test from their general practitioner during 2007 [95% confidence interval (CI) 5.6–7.0%; practice-based inter-quartile range 3.6–8.4%]. • PSA testing rates were 1.4% (95% CI 1.1–1.6%) in men aged 45–49, rising to 11.3% (95% CI 10.0–12.9%) at age 75–79 years (P for trend <0.001). • Testing rates were lowest in the three northern centres (3.5–5.7%) vs the three more southern centres (7.1–8.9%; P < 0.001). • For every 20 points increase in the index of multiple deprivation score, the proportion of men tested fell by 1.7% (95% CI −2.5 to −0.8%; P < 0.001). • Lower proportions of men were subsequently diagnosed with prostate cancer in practices testing more men (odds ratio for a one unit increase in the natural log of testing 0.76; 95% CI 0.60–0.97; P= 0.025). CONCLUSION • Overall levels of PSA testing in UK general practice remain low, but for those tested there are important variations by age, deprivation and geographical location that do not appear to reflect clinical need or the intention of current policy. • PSA testing in general practice is currently skewed towards older men, and current policy enabling all men to make an informed choice about PSA testing is not being effectively implemented as uptake clearly varies by socioeconomic status. • This reinforces the need for robust evidence regarding the costs and benefits of using the PSA test for the detection of localized prostate cancer in the UK, a full assessment of the health economic implications and a revision of the current policy." @default.
• W1887776136 created "2016-06-24" @default.
• W1887776136 creator A5012694886 @default.
• W1887776136 creator A5045609021 @default.
• W1887776136 creator A5049636639 @default.
• W1887776136 creator A5061314905 @default.
• W1887776136 creator A5065571043 @default.
• W1887776136 creator A5072541132 @default.
• W1887776136 creator A5078250568 @default.
• W1887776136 creator A5090783984 @default.
• W1887776136 date "2011-04-11" @default.
• W1887776136 modified "2023-10-17" @default.
• W1887776136 title "Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities" @default.
• W1887776136 cites W1511168152 @default.
• W1887776136 cites W1583264770 @default.
• W1887776136 cites W1969804281 @default.
• W1887776136 cites W1973576424 @default.
• W1887776136 cites W1984120719 @default.
• W1887776136 cites W1992768779 @default.
• W1887776136 cites W2003922832 @default.
• W1887776136 cites W2018009871 @default.
• W1887776136 cites W2039760601 @default.
• W1887776136 cites W2043165506 @default.
• W1887776136 cites W2054386661 @default.
• W1887776136 cites W2063431654 @default.
• W1887776136 cites W2081703330 @default.
• W1887776136 cites W2084192761 @default.
• W1887776136 cites W2092627833 @default.
• W1887776136 cites W2095761465 @default.
• W1887776136 cites W2107720777 @default.
• W1887776136 cites W2111007291 @default.
• W1887776136 cites W2112642061 @default.
• W1887776136 cites W2116518562 @default.
• W1887776136 cites W2121103668 @default.
• W1887776136 cites W2127488232 @default.
• W1887776136 cites W2132528779 @default.
• W1887776136 cites W2138320929 @default.
• W1887776136 cites W2156351746 @default.
• W1887776136 cites W2159803932 @default.
• W1887776136 cites W345879277 @default.
• W1887776136 doi "https://doi.org/10.1111/j.1464-410x.2011.10163.x" @default.
• W1887776136 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21481132" @default.
• W1887776136 hasPublicationYear "2011" @default.
• W1887776136 type Work @default.
• W1887776136 sameAs 1887776136 @default.
• W1887776136 citedByCount "67" @default.
• W1887776136 countsByYear W18877761362012 @default.
• W1887776136 countsByYear W18877761362013 @default.
• W1887776136 countsByYear W18877761362014 @default.
• W1887776136 countsByYear W18877761362015 @default.
• W1887776136 countsByYear W18877761362016 @default.
• W1887776136 countsByYear W18877761362017 @default.
• W1887776136 countsByYear W18877761362018 @default.
• W1887776136 countsByYear W18877761362019 @default.
• W1887776136 countsByYear W18877761362020 @default.
• W1887776136 countsByYear W18877761362021 @default.
• W1887776136 countsByYear W18877761362022 @default.
• W1887776136 countsByYear W18877761362023 @default.
• W1887776136 crossrefType "journal-article" @default.
• W1887776136 hasAuthorship W1887776136A5012694886 @default.
• W1887776136 hasAuthorship W1887776136A5045609021 @default.
• W1887776136 hasAuthorship W1887776136A5049636639 @default.
• W1887776136 hasAuthorship W1887776136A5061314905 @default.
• W1887776136 hasAuthorship W1887776136A5065571043 @default.
• W1887776136 hasAuthorship W1887776136A5072541132 @default.
• W1887776136 hasAuthorship W1887776136A5078250568 @default.
• W1887776136 hasAuthorship W1887776136A5090783984 @default.
• W1887776136 hasBestOaLocation W18877761361 @default.
• W1887776136 hasConcept C121608353 @default.
• W1887776136 hasConcept C126322002 @default.
• W1887776136 hasConcept C144024400 @default.
• W1887776136 hasConcept C149923435 @default.
• W1887776136 hasConcept C151730666 @default.
• W1887776136 hasConcept C167135981 @default.
• W1887776136 hasConcept C2775941076 @default.
• W1887776136 hasConcept C2776235491 @default.
• W1887776136 hasConcept C2777267654 @default.
• W1887776136 hasConcept C2780192828 @default.
• W1887776136 hasConcept C2781406297 @default.
• W1887776136 hasConcept C29456083 @default.
• W1887776136 hasConcept C71924100 @default.
• W1887776136 hasConcept C72563966 @default.
• W1887776136 hasConcept C86803240 @default.
• W1887776136 hasConceptScore W1887776136C121608353 @default.
• W1887776136 hasConceptScore W1887776136C126322002 @default.
• W1887776136 hasConceptScore W1887776136C144024400 @default.
• W1887776136 hasConceptScore W1887776136C149923435 @default.
• W1887776136 hasConceptScore W1887776136C151730666 @default.
• W1887776136 hasConceptScore W1887776136C167135981 @default.
• W1887776136 hasConceptScore W1887776136C2775941076 @default.
• W1887776136 hasConceptScore W1887776136C2776235491 @default.
• W1887776136 hasConceptScore W1887776136C2777267654 @default.
• W1887776136 hasConceptScore W1887776136C2780192828 @default.
• W1887776136 hasConceptScore W1887776136C2781406297 @default.
• W1887776136 hasConceptScore W1887776136C29456083 @default.
• W1887776136 hasConceptScore W1887776136C71924100 @default.
• W1887776136 hasConceptScore W1887776136C72563966 @default.
• W1887776136 hasConceptScore W1887776136C86803240 @default.

• next